Familiar Therapeutics has raised $5 Million in New Funding

According to filings with the U.S. Securities and Exchange Commission, Familiar Therapeutics has raised $5 Million in new Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Pioneer Fund, Icehouse Ventures and BreakTHRU

About Familiar Therapeutics
Familiar Therapeutics translates proven human medicines into novel therapeutics for companion animals, with the goal of making advanced treatments available through every veterinary clinic. The company focuses on serious diseases that affect dogs and cats, including cancer and immune disorders, using validated human drug targets and established safety data as the foundation for animal-specific development. Familiar partners with pharmaceutical, biotechnology, academic, and technology organizations, then conducts veterinary research, clinical studies, and regulatory work toward FDA approval. Its lead program, FAM-010, is an investigational form of doxorubicin being evaluated in a pilot study for dogs recently diagnosed with splenic hemangiosarcoma. Familiar states that FAM-010 is one of 13 programs bringing advances in human medicine to pets, and that the company has built those programs, signed several pharmaceutical partnerships, filed a provisional patent, and opened two drug development files with FDAs Center for Veterinary Medicine. The company was created by Elizabeth and Dan Knox after Elizabeths French Bulldog, Lily, was diagnosed with a terminal brain tumor, inspiring their broader mission to close the gap between human and veterinary medicine.

To learn more, visit https://familiartx.com/
Linkedin: https://www.linkedin.com/company/familiartx/

Contact:
Elizabeth Iorns, CEO
https://www.linkedin.com/in/elizabethiorns/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.